AI Investing Insights - Official Homepage

News

7.0

01-23aastocks

MICROPORT Rises Approximately 8% Following Favorable Profit Announcement

4.5

01-23aastocks

HSI Rises 231 Points as BABA-W and POP MART Surge 4%

4.0

01-08aastocks

Citi Resumes Coverage of MICROPORT with a Buy Rating and Target Price of HKD 16

4.0

2025-11-13aastocks

BofAS Raises MICROPORT (00853.HK) Price Target to $17, Maintains Buy Rating

4.5

2025-10-08aastocks

<Daily Summary> HSI Ends at 26,829, Decreasing by 128 Points; HSTI Finishes at 6,514, Down 36 Points; LONGFOR Falls More Than 4%; CGN MINING, SD GOLD, JIANGXI COPPER, MICROPORT, YSB Reach New Peaks; Market Trading Volume Increases

Money Flow

Over the past 66 trading days, overall net money flow is -33.71M, with retail investors contributing -4.45M and major investors adding -34.94M.

Net Buy $ Volume

Net Sell $ Volume

Citi

NULL

to

Buy

initiated

$16

2026-01-08

Reason

The analyst rating from Citi is a Buy, based on several key reasons: 1. Continuous improvement in the company's fundamentals. 2. A significant reduction in net loss of 66% year-over-year in the first half of 2025. 3. Expectations of a turnaround in the second half of 2025. 4. Potential upside from post-merger synergies. 5. Recognition of MICROPORT as one of the broker's top picks in the industry.

Citi

NULL

to

Buy

Price Target

$16

2026-01-08

initiated

The analyst rating from Citi is a Buy, based on several key reasons: 1. Continuous improvement in the company's fundamentals. 2. A significant reduction in net loss of 66% year-over-year in the first half of 2025. 3. Expectations of a turnaround in the second half of 2025. 4. Potential upside from post-merger synergies. 5. Recognition of MICROPORT as one of the broker's top picks in the industry.

BofA Securities

Buy

maintain

$17

2025-11-13

Reason

The analyst rating for MICROPORT (00853.HK) was reaffirmed as a Buy due to a better risk-reward profile. The company has a diversified portfolio of high-value consumables, and its surgical robotics business is expected to be a significant growth driver in the future, with projections indicating that surgical robots will contribute 19% of total revenue by 2034. Additionally, the broker raised its total revenue forecast for 2026-2034 and increased the target price from HKD16.8 to HKD17.

BofA Securities

Buy

Price Target

$17

2025-11-13

maintain

The analyst rating for MICROPORT (00853.HK) was reaffirmed as a Buy due to a better risk-reward profile. The company has a diversified portfolio of high-value consumables, and its surgical robotics business is expected to be a significant growth driver in the future, with projections indicating that surgical robots will contribute 19% of total revenue by 2034. Additionally, the broker raised its total revenue forecast for 2026-2034 and increased the target price from HKD16.8 to HKD17.

Morgan Stanley

Equalweight

maintain

$16

2025-09-30

Reason

The analyst rating for MICROPORT (00853.HK) is set at "Equalweight" due to several key factors highlighted in the Morgan Stanley report. The restructuring of its Cardiac Rhythm Management (CRM) business, including the acquisition of CRM by its subsidiary CARDIOFLOW-B, is seen as a significant cleanup event. This transaction is expected to address CRM's capital redemption obligations and reduce MICROPORT's financial expenses by refinancing senior convertible bonds at a lower interest rate of 2.8%. Additionally, the restructuring supports MICROPORT's goal to decrease its debt ratio from 70% to around 50% within 1-3 years, and further to 30-35% within 3-5 years. These developments contribute to the overall assessment of the company's financial health and future prospects, justifying the "Equalweight" rating.

Morgan Stanley

Equalweight

Price Target

$16

2025-09-30

maintain

The analyst rating for MICROPORT (00853.HK) is set at "Equalweight" due to several key factors highlighted in the Morgan Stanley report. The restructuring of its Cardiac Rhythm Management (CRM) business, including the acquisition of CRM by its subsidiary CARDIOFLOW-B, is seen as a significant cleanup event. This transaction is expected to address CRM's capital redemption obligations and reduce MICROPORT's financial expenses by refinancing senior convertible bonds at a lower interest rate of 2.8%. Additionally, the restructuring supports MICROPORT's goal to decrease its debt ratio from 70% to around 50% within 1-3 years, and further to 30-35% within 3-5 years. These developments contribute to the overall assessment of the company's financial health and future prospects, justifying the "Equalweight" rating.

Valuation Metrics

Forward PE

N/A

5Y Average PE

-202.37

Current PE

-2086.75

Overvalued PE

521.06

Undervalued PE

-925.81

Forward EV/EBITDA

N/A

5Y Average EV/EBITDA

-15.60

Current EV/EBITDA

17.39

Overvalued EV/EBITDA

45.16

Undervalued EV/EBITDA

-76.35

Forward PS

5Y Average PS

4.70

Current PS

2.17

Overvalued PS

9.22

Undervalued PS

0.18

Financials

AI Analysis

Annual

Quarterly

Trading Trends

Daily

Monthly

No data

Short Selling

People Also Watch